ANI Pharmaceuticals logo

ANI PharmaceuticalsNASDAQ: ANIP

Profile

Sector:

Healthcare

Country:

United States

IPO:

05 May 2000

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$1.18 B
-20%vs. 3y high
75%vs. sector
-61%vs. 3y high
77%vs. sector
-42%vs. 3y high
66%vs. sector
-45%vs. 3y high
38%vs. sector

Price

after hours | 26 min ago
$56.01-$2.27(-3.89%)

Dividend

No data over the past 3 years
$138.04 M$143.96 M
$138.04 M-$2.29 M

Analysts recommendations

Institutional Ownership

ANIP Latest News

ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November
globenewswire.com04 November 2024 Sentiment: -

PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at at two upcoming investor conferences as follows:

Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline
zacks.com01 November 2024 Sentiment: NEGATIVE

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET
globenewswire.com30 October 2024 Sentiment: POSITIVE

PRINCETON, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2024 financial results on Friday, November 8, 2024, prior to the market open.

ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06%
globenewswire.com25 October 2024 Sentiment: POSITIVE

PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Estradiol Gel, 0.06%. ANI's Estradiol Gel, 0.06% is the generic version of the reference listed drug (RLD) EstroGel® Gel, 0.06%.

ANI Pharmaceuticals to Present New Data Highlighting Membranous Nephropathy Research at American Society of Nephrology Kidney Week 2024
globenewswire.com24 October 2024 Sentiment: POSITIVE

Two poster presentations demonstrate ANI's commitment to research in membranous nephropathy care Two poster presentations demonstrate ANI's commitment to research in membranous nephropathy care

Why Investors Need to Take Advantage of These 2 Medical Stocks Now
zacks.com17 October 2024 Sentiment: POSITIVE

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
zacks.com16 October 2024 Sentiment: POSITIVE

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
zacks.com15 October 2024 Sentiment: POSITIVE

ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential
benzinga.com11 October 2024 Sentiment: POSITIVE

Piper Sandler has initiated coverage on ANI Pharmaceuticals ANIP, an integrated specialty pharmaceutical firm that develops and markets branded and generic medicines.

ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market
seekingalpha.com11 October 2024 Sentiment: POSITIVE

Today, we revisit small biopharma ANI Pharmaceuticals, as it is a GARP stock trading near technical support, with solid growth prospects. The company recently acquired Alimera Sciences for $380 million, boosting its rare disease segment with a couple of durable ophthalmology products. Analyst firms are generally bullish on the company's prospects and the stock trades at 12 times trailing earnings, despite revenue growth in the high teens.

What type of business is ANI Pharmaceuticals?

ANI Pharmaceuticals, Inc. is a pharmaceutical company. Founded in 2001 in the state of Delaware. The headquarters are located in Baudette, Minnesota. The company's main activities include the development, production, and marketing of branded and prescription pharmaceuticals. A wide range of products produced includes medications used to treat various diseases, including cardiovascular, neurological, endocrine, infectious, gastrointestinal, and dermatological diseases, pain relievers, as well as medications for cancer treatment, hormones, and steroids. The company has three manufacturing facilities and its own laboratories that not only control the quality of the raw materials used but also engage in the development of pharmaceuticals.

What sector is ANI Pharmaceuticals in?

ANI Pharmaceuticals is in the Healthcare sector

What industry is ANI Pharmaceuticals in?

ANI Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry

What country is ANI Pharmaceuticals from?

ANI Pharmaceuticals is headquartered in United States

When did ANI Pharmaceuticals go public?

ANI Pharmaceuticals initial public offering (IPO) was on 05 May 2000

What is ANI Pharmaceuticals website?

https://www.anipharmaceuticals.com

Is ANI Pharmaceuticals in the S&P 500?

No, ANI Pharmaceuticals is not included in the S&P 500 index

Is ANI Pharmaceuticals in the NASDAQ 100?

No, ANI Pharmaceuticals is not included in the NASDAQ 100 index

Is ANI Pharmaceuticals in the Dow Jones?

No, ANI Pharmaceuticals is not included in the Dow Jones index

When was ANI Pharmaceuticals the previous earnings report?

No data

When does ANI Pharmaceuticals earnings report?

The next expected earnings date for ANI Pharmaceuticals is 08 November 2024